Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Osivax has raised $10.5M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Osivax's investors include Bpifrance, Bill & Melinda Gates Foundation, European Innovation Council, National Institute of Allergy and Infectious Diseases, Anaxago.
Osivax is headquartered in Lyon, France.
Osivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.
Osivax is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Osivax — Funding & Investors." VCBacked, March 4, 2025, https://www.vcbacked.co/company/osivax. Accessed August 17, 2026.
VCBacked. (2025). Osivax — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/osivax
{{cite web |title=Osivax — Funding & Investors |url=https://www.vcbacked.co/company/osivax |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated